Hims & Hers Health stock is trading -39.24% below its average target price of $44.82 after marking a 1.0% during today's ...

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

The stock market fell sharply anew on Wednesday, with all major indices ending in the red, as investor sentiment was dampened ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Trial data data showed Lilly's experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer ...

The stock market has recently witnessed significant movements among key players in the technology and healthcare sectors.

Eli Lilly’s stock has hit a 52-week low at $697.35, nosediving over 10% this past week, which has investors holding their ...

Shares of technology tumbled with Apple Inc. leading the charge lower. That decline came on the heels of President Donald ...

Shares of Eli Lilly, the seller of Zepbound, were down 2.7% to $718.50 after the close on Friday. Novo Nordisk, the maker of Wegovy, saw its stock decline 1.4% to $61.67. Shares of Hims & Hers, a ...

One way to get an idea of the market sentiment on a stock is to check its rate of institutional ownership. In the case of Hims & Hers Health, institutional investors own 79.0% of the shares, which ...

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) gapped down before the market opened on Wednesday after an insider sold shares in the company. The stock had previously closed at ...